NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
New Neonatal Study Adds to Body of Clinical Evidence Demonstrating Masimo SET ® Pulse Oximetry’s Unique Ability to Improve Care NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) provides ...
Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
Furthering its move into the neonatal space, this morning non-invasive patient monitoring device and sensor maker Masimo announced that it landed FDA clearance for its acoustic respiration sensor, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results